IRVING, Texas and PHOENIX - Caris Diagnostics (Caris Dx) -a provider of integrated anatomic pathology and oncology testing services, announced the appointment of a nationally-renowned oncologist, David Loesch, MD, as Director of Oncology, Clinical Trials and Services.

"Dr. Loesch has been a recognized leader in the oncology community for years, with a firm commitment to personalized care and oncology research. He will be instrumental to our goal of becoming the trusted provider of molecular profiling for cancer patients," says David D. Halbert, Chairman and CEO of Caris Dx. "The appointment of Dr. Loesch provides further evidence of our organizational commitment to the oncology market, as Caris Dx begins to define the future of individualized oncology care."

Loesch is widely recognized as one of the nation's foremost authorities on breast cancer diagnosis, treatment and research. He has served as Co-Chairman of the Breast Cancer Committee for the US Oncology (USO) Network and has been a practicing medical oncologist for over 18 years. In 2006, he was bestowed the Indiana Breast Cancer Alliance (IBCA) Medical Researcher "Excellence" Award and in 2007 was named the Indiana Breast Cancer Researcher of the Year by the Indiana Breast Cancer Coalition.

"This is an exciting time for Caris Dx, my clinical colleagues, and myself, as the field of clinical oncology rapidly shifts towards the molecular paradigm," Loesch says. "I look forward to helping Caris Dx develop our next generation Target Now(r) oncology testing service and strategically position ourselves to build one of the most robust and integrated molecular testing programs in the nation."